case_images: PMC10985247_01
case_images: Time course of the treatment. EPS, extrapyramidal symptom. Created with .
case_images: fpsyt-15-1363051-g001.jpg
case_images: PMC10985247_01_fpsyt-15-1363051-g001.jpg
case_images: f1
case_images: The overall time course of treatment is summarized in  Figure 1 .
case_images: Pharmacokinetic pathways of risperidone, brexpiprazole, aripiprazole, fluphenazine, and olanzapine. Metabolites in bold are the major metabolites of designated drugs. CYP2D6, cytochrome P450 Family 2 Subfamily D Member 6; CYP3A4/5, cytochrome P450 Family 3 Subfamily A Member 4/5; CYP2C8, cytochrome P450 Family 2 Subfamily C Member 8; CYP1A2, cytochrome P450 Family 1 Subfamily A Member 2; ABCB1, ATP-binding cassette sub-family B member 1; ABCG2, ATP-binding cassette super-family G member 2; UGT1A4, Uridine 5'-diphospho-glucuronosyltransferase Family 1 Subfamily A Member 4; UGT2B10, Uridine 5' diphospho-glucuronosyltransferase Family 2 Subfamily B Member 10; FMO3, flavin monooxygenase 3. The figure was created with BioRender.com and was inspired based on Whirl-Carrillo et al. and Soria-Chacartegui et al..
case_images: fpsyt-15-1363051-g002.jpg
case_images: PMC10985247_01_fpsyt-15-1363051-g002.jpg
case_images: f2
case_images: Based on the pharmacokinetic pathways of the majority of prescribed drugs causing ADRs ( Figure 2 ), pharmacogenetic testing was performed by analyzing common functional variants in CYP2D6, CYP3A4, CYP1A2, CYP3A5, ABCB1, and ABCG2.